BCL2 and acute myeloid leukemia: Designed to directly initiate the intrinsic pathway of apoptosis at the mitochondria (37), the targeted therapy venetoclax (i.e., a BCL-2 inhibitor and a mediator of BAX/BAK-dependent apoptosis) was granted regular Food and Drug Administration approval for the treatment of AML in 2020 (38).